Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set
NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket
Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters
The pricing matters because Omeros is trying to turn a long-running development story into a launch, with Yartemlea (narsoplimab-wuug) positioned as the first and only approved inhibitor of the lectin pathway of complement — part of the…
